Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IMVT Immunovant > Detailed Quotes

IMVT Immunovant

5.580
+0.200+3.72%
Close 09/30 16:00 ET
5.5800.0000.00%
Post Mkt Price 09/30 17:50 ET
High
5.690
Open
5.510
Turnover
8.93M
Low
5.091
Pre Close
5.380
Volume
1.62M
Market Cap
650.50M
P/E(TTM)
Loss
52wk High
9.535
Shares
116.58M
P/E(Static)
Loss
52wk Low
3.145
Float Cap
185.92M
Bid/Ask %
75.00%
Historical High
53.750
Shs Float
33.32M
Volume Ratio
0.77
Historical Low
3.145
Dividend TTM
--
Div Yield TTM
--
P/B
1.49
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
4.86%
Amplitude
11.13%
Avg Price
5.517
Lot Size
1
Float Cap
185.92M
Bid/Ask %
75.00%
Historical High
53.750
Shs Float
33.32M
Volume Ratio
0.77
Historical Low
3.145
Dividend TTM
--
P/B
1.49
Dividend LFY
--
Turnover Ratio
4.86%
Amplitude
11.13%
Avg Price
5.517
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
CEO: Dr. Peter Salzmann, M.B.A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...